Searching research on senior citizen's gastric cancer on clinical effect and safety of TS-1

Searching research on senior citizen's gastric cancer on clinical effect and safety of TS-1 - Searching research on senior citizen's gastric cancer on clinical effect and safety of TS-1

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-C000000285

Enrollment

Registered

2005-11-18

Start date

2004-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

senior citizen's gastric cancer

Interventions

TS1: 50 or 80 or 100 or 120 mg/body/day, orally 28 days, every 6 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)With pathologically proven gastric cancer 2) With at least one measurable lesion (RECIST) 3) Age 75 years old or more 4) ECOG performance status=3 months 8) With written informed consent 9) Case who has understanding that can secure S-1 compliance enough

Exclusion criteria

Exclusion criteria: 1.History of severe drug allergic reaction 2.Severe Bone marrow suppression,renal and liver function disturbance 3.Concomitant therapy with another anticancer drug or flucytocine 4.Marked pleural effusion or ascites 5.Symptomatic brain metastasis 6.Intestinal fresh hemorrhage 7.Active secondary cancer 8.Accompanied serious diseases 9.Severe Ischemic heart disease or Arrhythmia which requires treatment 10.Watery diarrhea 11.Decision as ineligible by principal investigator

Design outcomes

Primary

Measure	Time frame
Response rate	—

Secondary

Measure	Time frame
TTF, OS, Safety, Home treatment period, home treatment rate	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026